Can a new PET scan light up hidden adrenal tumors causing high blood pressure?

NCT ID NCT05815069

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This trial is testing whether a new radioactive tracer, [18F]AlF-NOTA-pentixather, can accurately identify aldosterone-producing adenomas (benign adrenal tumors) in people with primary aldosteronism—a condition where the adrenal glands make too much aldosterone, leading to high blood pressure and low potassium. About 20 participants with suspected primary aldosteronism will receive the tracer and undergo a PET/CT scan. The scan's results will be compared with the final pathology after surgery to see how sensitive and specific the test is for diagnosing these tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A radioactive tracer called [18F]AlF-NOTA-pentixather, given by injection for a PET/CT scan
What this could lead to
If it works, this could offer a more accurate, non-invasive way to find aldosterone-producing adrenal tumors, potentially guiding better treatment and avoiding unnecessary surgery.
What could go wrong
This is a small early-stage study (20 people), so results may not apply broadly. The tracer's accuracy needs confirmation against surgical findings, and there may be false positives or negatives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALDOSTERONE-PRODUCING ADENOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sichuan Academy of Medical Sciences.Sichuan Provincial People's Hospital

    Chengdu, Sichuan, 610072, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.